CA5A抗体;CA5A Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-5: K562, A549, HT-29, 231 and HepG2 cell lysates, Primary antibody: P12998(CA5A Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

The CA5A antibody targets carbonic anhydrase 5A (CA-VA), a mitochondrial enzyme encoded by the *CA5A* gene. As part of the carbonic anhydrase family, CA5A catalyzes the reversible hydration of carbon dioxide to bicarbonate and protons, playing a critical role in pH homeostasis, metabolic pathways, and mitochondrial function. CA5A is highly expressed in metabolically active tissues, such as the liver, kidney, and pancreas, where it supports urea synthesis, gluconeogenesis, and energy metabolism. Dysregulation of CA5A has been implicated in metabolic disorders, including hyperammonemia and mitochondrial diseases, due to its role in nitrogen metabolism and mitochondrial bioenergetics.

CA5A antibodies are widely utilized in research to investigate protein expression, localization, and functional interactions. They are essential tools in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study CA5A's tissue distribution and alterations in disease models. Recent studies also explore CA5A's potential as a biomarker in cancer, as abnormal expression correlates with tumor progression and metabolic reprogramming. Commercial CA5A antibodies are typically validated for specificity using knockout controls or siRNA-based silencing. Researchers prioritize antibodies with high affinity and minimal cross-reactivity to other CA isoforms (e.g., CA-II or CA-IX) to ensure accurate experimental outcomes. Continued interest in CA5A stems from its therapeutic potential in targeting metabolic vulnerabilities in cancer and genetic disorders.